Menu
Back to Journals » International Journal of Nephrology and Renovascular Disease » Volume 6
Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration
Authors Honore PM, Jacobs R, Lochy S, De Waele E, Van Gorp V, De Regt J, Martens G, Joannes-Boyau O, Boer W, Spapen HD
Received 15 January 2013
Accepted for publication 4 April 2013
Published 7 June 2013 Volume 2013:6 Pages 107—111
DOI https://doi.org/10.2147/IJNRD.S42791
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Patrick M Honore,1 Rita Jacobs,1 Stijn Lochy,1 Elisabeth De Waele,1 Viola Van Gorp,1 Jouke De Regt,1 Geert Martens,1 Olivier Joannes-Boyau,2 Willem Boer,3 Herbert D Spapen1
1Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium; 2Haut Leveque University Hospital of Bordeaux, University of Bordeaux 2, Pessac, France; 3Ziekenhuis Oost-Limburg, Genk, Belgium
Abstract: We describe a patient with severe New Delhi metallo-β-lactamase-1 Escherichia coli infection who developed convulsions rapidly followed by acute respiratory muscle weakness and apnea while receiving intravenous colistin. Toxic levels of colistin were rapidly removed by hemofiltration and, more specifically, by hemoadsorption.
Keywords: colistin, neurotoxicity, convulsions, neuromuscular blockade, apnea, hemofiltration, hemoadsorption, CVVH, CRRT
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.